DDInter256 DDInter629
Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.[A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.[A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634]
Butabarbital {u} (Compound) resembles {v} (Compound) Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Butabarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Butabarbital {u} (Compound) resembles {v} (Compound) Phenobarbital
Phenobarbital {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Butabarbital {u} (Compound) resembles {v} (Compound) Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Butabarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Butabarbital {u} (Compound) resembles {v} (Compound) Amobarbital
Amobarbital {u} (Compound) resembles {v} (Compound) Secobarbital
Secobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Butabarbital {u} (Compound) resembles {v} (Compound) Phenobarbital
Phenobarbital {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Butabarbital {u} (Compound) resembles {v} (Compound) Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Butabarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Butabarbital {u} (Compound) resembles {v} (Compound) Phenobarbital
Phenobarbital {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Butabarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Butabarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Butabarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital may lead to a major life threatening interaction when taken with Eliglustat
Butabarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Butabarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Butabarbital (Compound) resembles Amobarbital (Compound) and Amobarbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Butabarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Butabarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Butabarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Butabarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat